The Power and Potential of Doxorubicin‐DNA Adducts

@article{Cutts2005ThePA,
  title={The Power and Potential of Doxorubicin‐DNA Adducts},
  author={S. Cutts and A. Nudelman and A. Rephaeli and D. Phillips},
  journal={IUBMB Life},
  year={2005},
  volume={57}
}
Doxorubicin (trade name Adriamycin) is a widely used anticancer agent which exhibits good activity against a wide range of tumors. Although the major mode of action appears to be normally as a topoisomerase II poison, it also exhibits a number of other cellular responses, one of which is the ability to form adducts with DNA. For adduct formation doxorubicin must react with cellular formaldehyde to form an activated Schiff base which is then able to form an aminal (N‐C‐N) linkage to the… Expand
Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate
Barminomycin, a model for the development of new anthracyclines.
Analysis of cross-linking between DNA and anthracyclines
Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
IS METABOLIC ACTIVATION OF TOPOISOMERASE II POISONS IMPORTANT IN THE MECHANISM OF CYTOTOXICITY?
Stability and iron coordination in DNA adducts of Anthracycline based anti-cancer drugs.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Characterization of covalent adriamycin-DNA adducts.
Barminomycin functions as a potent pre-activated analogue of Adriamycin.
...
1
2
3
4
5
...